Welcome to our dedicated page for Tonix Pharmaceut news (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceut stock.
Tonix Pharmaceuticals Holding Corp (TNXP) is a clinical-stage biopharmaceutical company developing innovative therapeutics for central nervous system disorders, immunology, and infectious diseases. This page provides timely updates on TNXP's clinical trials, regulatory milestones, and strategic initiatives.
Key resources for investors include press releases covering product development progress, partnership announcements, and financial reports. Our curated news collection helps track TNXP's pipeline candidates like TNX-102 SL for fibromyalgia and Tonmya™ for PTSD management.
Stay informed about developments in migraine therapeutics, rare disease research, and vaccine programs. Content categories include FDA communications, clinical trial results, intellectual property updates, and market expansion activities.
Bookmark this page for direct access to verified TNXP updates. Check regularly for new developments in biopharmaceutical innovation impacting patient care and treatment paradigms.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced it regained compliance with Nasdaq’s minimum bid price requirement, closing at or above $1.00 per share for 10 consecutive days. This compliance ensures continued listing on The Nasdaq Capital Market. Tonix is a clinical-stage biopharmaceutical company focused on developing therapeutics across various areas, including CNS, rare diseases, immunology, and infectious diseases. Key candidates include TNX-102 SL for fibromyalgia and Long COVID, TNX-1300 for cocaine intoxication, and TNX-801 for smallpox and monkeypox. Interim data for various studies is expected throughout 2023.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced an oral presentation by Dr. Tom Hobman at the 2nd Wnt & β-catenin Targeted Drug Development Conference on January 26, 2023. The presentation, titled “Targeting the Wnt/β-catenin pathway as a broad-spectrum antiviral strategy,” highlighted research on Wnt/β-catenin signaling pathway inhibitors as potential broad-spectrum antivirals against SARS-CoV-2. The CEO emphasized the need for such therapeutics to combat future pandemics. Tonix's lead candidate, TNX-102 SL, is in mid-Phase 3 for fibromyalgia, with interim data expected in mid-2023, further underlining their commitment to developing innovative therapies.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced the publication of a research paper detailing the development of rapid imaging assays for therapeutic antibodies against the monkeypox virus. This research was conducted at their Infectious Disease R&D Center in Frederick, Maryland. The study demonstrated the efficacy of the TNX-3400 platform in identifying antibodies that can neutralize the vaccinia virus, which is akin to monkeypox. The company aims to leverage this technology for combination therapies targeting monkeypox and smallpox. The TNX-3400 platform serves as a foundation for potential broad-spectrum antiviral treatments.
Tonix Pharmaceuticals has appointed Dr. Zeil Rosenberg as Executive Vice President, Medical, to lead clinical development for its vaccine and antiviral programs. Dr. Rosenberg will oversee key candidates like TNX-801 for smallpox and monkeypox, TNX-1850 for COVID-19, and monoclonal antibodies TNX-3600 and TNX-3800 targeting severe COVID-19 in immunocompromised patients. His extensive experience in infectious disease and successful vaccine trials from his previous positions at PPD and BD is expected to strengthen Tonix's clinical development efforts during a critical time for its product pipeline.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that CEO Seth Lederman will present at Biotech Showcase 2023 from January 9-11, 2023, at Hilton San Francisco Union Square. The presentation is scheduled for January 10 at 3:00 p.m. PT. A live webcast will be available on the company’s website. Tonix focuses on developing therapeutics for various diseases, with lead candidate TNX-102 SL in mid-Phase 3 for fibromyalgia. Other programs target Long COVID, cocaine intoxication, chronic migraine, major depressive disorder, and infectious diseases.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) has randomized 50% of participants in the Phase 3 RESILIENT study of TNX-102 SL for fibromyalgia. An interim analysis by an Independent Data Monitoring Committee (IDMC) is anticipated in Q2 2023, with topline results expected in Q4 2023. Positive outcomes in RESILIENT, combined with past positive results from the RELIEF study, could support an NDA submission. Fibromyalgia affects 6-12 million adults in the U.S., highlighting the need for new non-opioid treatments, as current options have not satisfied patient needs since 2009.
Tonix Pharmaceuticals (Nasdaq: TNXP) has secured an exclusive license from Curia Global, Inc. for the development of three humanized murine monoclonal antibodies aimed at treating or preventing SARS-CoV-2 infections. This move comes as existing monoclonal antibody therapies struggle with new COVID-19 variants. CEO Seth Lederman emphasized the need for next-generation treatments, especially for immunocompromised individuals at higher risk of severe outcomes. Tonix aims to leverage its capabilities to expand its COVID-19 therapeutic pipeline.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced a sponsored research agreement with Boston Children's Hospital to evaluate TNX-1500, an Fc-modified anti-CD40L monoclonal antibody, for preventing graft-versus-host disease (GvHD) after hematopoietic stem cell transplantation (HCT). The study, led by Dr. Leslie Kean, aims to assess TNX-1500's effectiveness in modifying GvHD progression in animal models, supporting future human trials. A Phase 1 study for TNX-1500 is expected to start in the first half of 2023, targeting improved treatment outcomes for hematologic malignancies.
Tonix Pharmaceuticals (Nasdaq: TNXP) presented data on TNX-801, a live horsepox virus vaccine, at the World Vaccine and Immunotherapy Congress. CEO Seth Lederman emphasized that TNX-801 could offer better protection against monkeypox and smallpox compared to modern vaccines. The company plans to initiate a Phase 1 clinical study in Kenya in H1 2023 and has reported positive data from non-human primates showing complete protection from monkeypox. TNX-801 is based on the 1976 horsepox strain, suggesting it has a close genetic link to Edward Jenner's original smallpox vaccine.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) presented data on its fully human anti-SARS-CoV-2 monoclonal antibody platform at the World Antiviral Congress 2022. Collaborating with Columbia University, the project aims to enhance understanding of immune responses to COVID-19 and develop targeted therapeutics. CEO Seth Lederman emphasized the necessity for second-generation monoclonal antibody treatments due to new variants and declining efficacy of existing ones. The company is exploring rapid development of novel therapeutics from patient samples, showcasing its capabilities in biologics manufacturing.
